The prostate-specific membrane antigen: Lessons and current clinical implications from 20 years of research

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 3, 2014, Pages 272-279

  Ristau, Benjamin T ^a   O'Keefe, Denise S ^a   Bacich, Dean J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer therapeutics; Folate; Prostate cancer; Prostate specific membrane antigen; Tumor markers

Indexed keywords

APTAMER; CAPROMAB PENDETIDE IN 111; CELL SURFACE MARKER; GLUTAMATE CARBOXYPEPTIDASE II; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RNA; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; TUMOR MARKER;

CANCER RESEARCH; CAUSE OF DEATH; CLINICAL TRIAL (TOPIC); CLONING; CONJUGATE; FOLATE METABOLISM; GLEASON SCORE; HUMAN; IMMUNOTHERAPY; INTESTINE ABSORPTION; KIDNEY; KIDNEY CARCINOMA; KIDNEY PROXIMAL TUBULE; MEDLINE; NERVOUS SYSTEM; NERVOUS SYSTEM DEVELOPMENT; ONCOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE EPITHELIUM; REVIEW; SMALL INTESTINE; UNITED STATES; MALE; PROSTATIC NEOPLASMS;

ANTIGENS, SURFACE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84897043505     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.09.003     Document Type: Review

References (60)

1. D'Amico A.V., Whittington R., Malkowicz B., et al. Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer. J Urol 2000, 164:759-763.
2. Schroder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320-1328.
3. Miles B.J., Shalev M., Aguilar-Cordova E., et al. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther 2001, 12:1955-1967.
4. Carter H.B., Albertsen P.C., Barry M.J., et al. Early detection of prostate cancer: AUA guideline. J Urol 2013, 190:419-426.
5. Moyer V.A. Force USPST. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012, 157:120-134.
6. Makovey I., Stephenson A.J., Haywood S. Response to the U.S. Preventative Services Task Force decision on prostate cancer screening. Curr Urol Rep 2013, 14:168-173.
7. Israeli R.S., Powell C.T., Fair W.R., Heston W.D. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993, 53:227-230.
8. Carter R.E., Feldman A.R., Coyle J.T. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci U S America 1996, 93:749-753.
9. Barinka C., Rojas C., Slusher B., Pomper M. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr Med Chem 2012, 19:856-870.
10. Mhawech-Fauceglia P., Zhang S., Terracciano L., et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology 2007, 50:472-483.
11. Sacha P., Zamecnik J., Barinka C., et al. Expression of glutamate carboxypeptidase II in human brain. Neuroscience 2007, 144:1361-1372.
12. Zhao R., Matherly L.H., Goldman I.D. Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. Expert Rev Mol Med 2009, 11:e4.
13. Shafizadeh T.B., Halsted C.H. gamma-Glutamyl hydrolase, not glutamate carboxypeptidase II, hydrolyzes dietary folate in rat small intestine. J Nutr 2007, 137:1149-1153.
14. Neale J.H., Bzdega T., Wroblewska B. N-acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system. J Neurochem 2000, 75:443-452.
15. Zollinger M., Amsler U., Do K.Q., Streit P., Cuenod M. Release of N-acetylaspartylglutamate on depolarization of rat brain slices. J Neurochem 1988, 51:1919-1923.
16. Niswender C.M., Conn P.J. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 2010, 50:295-322.
17. Robinson M.B., Blakely R.D., Couto R., Coyle J.T. Hydrolysis of the brain dipeptide N-acetyl-l-aspartyl-l-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. J Biol Chem 1987, 262:14498-14506.
18. Feng J.F., Gurkoff G.G., Van K.C., et al. NAAG peptidase inhibitor reduces cellular damage in a model of TBI with secondary hypoxia. Brain Res 2012, 1469:144-152.
19. Thomas A.G., Wozniak K.M., Tsukamoto T., et al. Glutamate carboxypeptidase II (NAALADase) inhibition as a novel therapeutic strategy. Adv Exp Med Biol 2006, 576:327-337. [Discussion 361-323].
20. Zuo D., Bzdega T., Olszewski R.T., Moffett J.R., Neale J.H. Effects of N-acetylaspartylglutamate (NAAG) peptidase inhibition on release of glutamate and dopamine in prefrontal cortex and nucleus accumbens in phencyclidine model of schizophrenia. J Biol Chem 2012, 287:21773-21782.
21. Haffner M.C., Kronberger I.E., Ross J.S., et al. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol 2009, 40:1754-1761.
22. Baccala A., Sercia L., Li J., Heston W., Zhou M. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology 2007, 70:385-390.
23. Al-Ahmadie H.A., Olgac S., Gregor P.D., et al. Expression of prostate-specific membrane antigen in renal cortical tumors. Mod Pathol 2008, 21:727-732.
24. Samplaski M.K., Heston W., Elson P., Magi-Galluzzi C., Hansel D.E. Folate hydrolase (prostate-specific membrane [corrected] antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature. Mod Pathol 2011, 24:1521-1529.
25. Horoszewicz J.S., Kawinski E., Murphy G.P. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987, 7:927-935.
26. Bostwick D.G., Pacelli A., Blute M., Roche P., Murphy G.P. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998, 82:2256-2261.
27. Wright G.L., Haley C., Beckett M.L., Schellhammer P.F. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1995, 1:18-28.
28. Yao V., Bacich D.J. Prostate specific membrane antigen (PSMA) expression gives prostate cancer cells a growth advantage in a physiologically relevant folate environment in vitro. Prostate 2006, 66:867-875.
29. Yao V., Berkman C.E., Choi J.K., O'Keefe D.S., Bacich D.J. Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid. Prostate 2010, 70:305-316.
30. Wright G.L., Grob B.M., Haley C., et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996, 48:326-334.
31. Perner S., Hofer M.D., Kim R., et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 2007, 38:696-701.
32. Murphy G.P., Maguire R.T., Rogers B., et al. Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostatic cancer patients. Prostate 1997, 33:281-285.
33. Foss C.A., Mease R.C., Cho S.Y., Kim H.J., Pomper M.G. GCPII imaging and cancer. Curr Med Chem 2012, 19:1346-1359.
34. Rosenthal S.A., Haseman M.K., Polascik T.J. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. Tech Urol Mar 2001, 7:27-37.
35. Hardie A.D., Rieter W.J., Bradshaw M.L., Gordon L.L., Young M.A., Keane T.E. Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion-weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer. World J Urol 2013, [Epub ahead of print. PMID:23595605].
36. Akin O., Hricak H. Imaging of prostate cancer. Radiol Clin N Am 2007, 45:207-222.
37. Troyer J.K., Feng Q., Beckett M.L., Wright G.L. Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen. Urol Oncol 1995, 1:29-37.
38. Smith-Jones P.M., Vallabahajosula S., Goldsmith S.J., et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res 2000, 60:5237-5243.
39. Pandit-Taskar N., O'Donoghue J.A., Morris M.J., et al. Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy. J Nucl Med 2008, 49:1066-1074.
40. Alt K., Wiehr S., Ehrlichmann W., et al. High-resolution animal PET imaging of prostate cancer xenografts with three different 64Cu-labeled antibodies against native cell-adherent PSMA. Prostate 2010, 70:1413-1421.
41. Rockey W.M., Huang L., Kloepping K.C., Baumhover N.J., Giangrande P.H., Schultz M.K. Synthesis and radiolabeling of chelator-RNA aptamer bioconjugates with copper-64 for targeted molecular imaging. Bioorg Med Chem 2011, 19:4080-4090.
42. Lapi S.E., Wahnishe H., Pham D., et al. Assessment of an 18 F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. J Nucl Med 2009, 50:2042-2048.
43. Chen Y., Pullambhatla M., Banerjee S.R., et al. Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen. Bioconjug Chem 2012, 23:2377-2385.
44. Cho S.Y., Gage K.L., Mease R.C., et al. Biodistribution, tumor detection, and radiation dosimetry of 18 F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med 2012, 53:1883-1891.
45. Barrett J.A., Coleman R.E., Goldsmith S.J., et al. First-in-man evaluation of two high-affinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med 2013, 54:380-387.
46. Cookson M.S., Roth B.J., Dahm P., et al. Castration-resistant prostate cancer: AUA guideline. J Urol 2013, 190:429-438.
47. Sokoloff R.L., Norton K.C., Gasior C.L., Marker K.M., Grauer L.S. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. Prostate 2000, 43:150-157.
48. Deb N., Goris M., Trisler K., et al. Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clin Cancer Res 1996, 2:1289-1297.
49. Kahn D., Austin J.C., Maguire R.T., Miller S.J., Gerstbrein J., Williams R.D. A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy. Cancer Biother Radiopharm 1999, 14:99-111.
50. 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005, 23:4591-4601.
51. Tagawa ST, Milowski MI, Morris M. Phase II trial of 177 Lutetium radiolabeled anti-prostate specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic castrate resistant prostate cancer (metCRPC). J Clin Oncol 2008;28(Suppl. 15).
52. Tagawa S.T., Vallabhajosula S., Osborne J., et al. Phase I trial of fractionated-dose 177 lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monocloncal antibody J591 (177Lu-J591) in patients with metastatic castration-resistant prostate cancer. Journal of Clinical Oncology 2010, 28(15S):4667.
53. Galsky M.D., Eisenberger M., Moore-Cooper S., et al. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol 2008, 26:2147-2154.
54. Akhtar N.H., Pail O., Saran A., Tyrell L., Tagawa S.T. Prostate-specific membrane antigen-based therapeutics. Adv Urol 2012, 2012:973820.
55. Denmeade S.R., Mhaka A.M., Rosen D.M., et al. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Sci Transl Med 2012, 4:140ra186.
56. SJ Jeske, Milowski MI, CR S, KA S, Bander N, Nanus DM. Phase II trial of the anti-prostate specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 plus low-dose interleukin-2 (IL-2) in patients with recurrent prostate cancer. J Clin Oncol 2007;25(Suppl. 18): [Abstract 15558].
57. Slovin S.F., Kehoe M., Durso R., et al. A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer. Vaccine 2013, 31:943-949.
58. Troyer J.K., Beckett M.L., Wright G.L. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 1997, 30:232-242.
59. Ayala G.E., Dai H., Powell M., et al. Cancer-related axonogenesis and neurogenesis in prostate cancer. Clin Cancer Res 2008, 14:7593-7603.
60. Xiao X.L., Ma D.L., Wu J., Tang F.R. Metabotropic glutamate receptor 5 (mGluR5) regulates proliferation and differentiation of neuronal progenitors in the developmental hippocampus. Brain Res 2013, 1493:1-12.